TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE)…
